https://www.channelnewsasia.com/singapore/moh-covid-19-vaccination-children-singapore-2372631
SINGAPORE: The Health Sciences Authority (HSA) has extended the authorisation of the Pfizer-BioNTech/Comirnaty COVID-19 vaccine for use in children aged between five and 11, with inoculations set to begin before the end of the year.
“The vaccination regimen is to be administered as a two-dose primary series, 21 days apart, but given at a lower dose (10 microgrammes) than that used for individuals aged 12 years and above (30 microgrammes),” HSA said in a news release late on Friday (Dec 10).
This is the first time that a COVID-19 vaccine has been authorised in Singapore for use in the five to 11 age group.
“HSA has conducted a thorough evaluation of the data in consultation with two groups of experts from HSA’s Medicines Advisory Committee and Panel of Infectious Diseases Experts,” the agency said.
“Based on the current available data, the benefits outweighed the risks for use in the young population, and the vaccine met the quality, safety and efficacy standards.”
The Ministry of Health (MOH) said that the multi-ministry task force had accepted the recommendation by the Expert Committee on COVID-19 Vaccination to use the paediatric doses of the Pfizer-BioNTech/Comirnaty COVID-19 vaccine for children aged between five and 11.
The committee also assessed that the benefits of the jab outweigh the risks when used in a paediatric dosage for children aged five to 11, "especially given ongoing community transmission and the emergence of the Omicron variant", MOH said.
“Vaccination for this group will commence before the end of this year, and once we receive deliveries of the vaccine doses,” the ministry added.
MOH said that a new supply agreement with Pfizer-BioNTech for the vaccine had been signed, and the ministry expects the shipment to arrive before the end of December.
"MOH will work with the Ministry of Education (MOE) and the Early Childhood Development Agency (ECDA) to roll out vaccinations for this school-going age group," it said, adding that more details would be announced by MOE and ECDA shortly.
SINGAPORE: The Health Sciences Authority (HSA) has extended the authorisation of the Pfizer-BioNTech/Comirnaty COVID-19 vaccine for use in children aged between five and 11, with inoculations set to begin before the end of the year.
“The vaccination regimen is to be administered as a two-dose primary series, 21 days apart, but given at a lower dose (10 microgrammes) than that used for individuals aged 12 years and above (30 microgrammes),” HSA said in a news release late on Friday (Dec 10).
This is the first time that a COVID-19 vaccine has been authorised in Singapore for use in the five to 11 age group.
“HSA has conducted a thorough evaluation of the data in consultation with two groups of experts from HSA’s Medicines Advisory Committee and Panel of Infectious Diseases Experts,” the agency said.
“Based on the current available data, the benefits outweighed the risks for use in the young population, and the vaccine met the quality, safety and efficacy standards.”
The Ministry of Health (MOH) said that the multi-ministry task force had accepted the recommendation by the Expert Committee on COVID-19 Vaccination to use the paediatric doses of the Pfizer-BioNTech/Comirnaty COVID-19 vaccine for children aged between five and 11.
The committee also assessed that the benefits of the jab outweigh the risks when used in a paediatric dosage for children aged five to 11, "especially given ongoing community transmission and the emergence of the Omicron variant", MOH said.
“Vaccination for this group will commence before the end of this year, and once we receive deliveries of the vaccine doses,” the ministry added.
MOH said that a new supply agreement with Pfizer-BioNTech for the vaccine had been signed, and the ministry expects the shipment to arrive before the end of December.
"MOH will work with the Ministry of Education (MOE) and the Early Childhood Development Agency (ECDA) to roll out vaccinations for this school-going age group," it said, adding that more details would be announced by MOE and ECDA shortly.